Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...
Hosted on MSN21d
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug TagCandel Therapeutics, Inc. CADL announced that the FDA has granted orphan drug designation to its lead investigational adenovirus immunotherapy candidate, CAN-2409, for the treatment of pancreatic ...
NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...
April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...
Shares of Candel Therapeutics Inc. CADL, -5.31% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment. Pancreatic cancer patients who ...
Candel Therapeutics shares were up 68%, to $2.82, after the company said it saw positive interim data from a phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The stock hit ...
Friday, Candel Therapeutics Inc CADL shares are trading higher on heavy volume with a session volume of 7.89 million versus the average volume of 2.37 million, as per data from Benzinga Pro.
Results come after Candel downsized to focus on core assets Shares of Candel Therapeutics Inc. (CADL) climbed 15% early Friday after the company released new data from a trial of its experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback